Korea's Celltrion To Supply Biosimilars To Europe And Japan This Year, Boosting Forecast
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's biosimilar front-runner Celltrion said it would provide biosimilar products of Roche's oncology agent Herceptin (trastuzumab) and Johnson & Johnson's rheumatoid arthritis agent Remicade (infliximab) to Europe and Japan this year worth KRW 293 billion ($263.61 million)
You may also be interested in...
Korea Begins To Assess Public Health, Industry Fallout From Japan Disaster
SEOUL - While a growing number of countries such as the U.S., Italy, France, Australia, New Zealand, Britain, China, India and Kyrgyzstan are urging their nationals in Japan to evacuate, South Korea on Thursday started checking radiation levels of people coming into the country from Japan
Korea Begins To Assess Public Health, Industry Fallout From Japan Disaster
SEOUL - While a growing number of countries such as the U.S., Italy, France, Australia, New Zealand, Britain, China, India and Kyrgyzstan are urging their nationals in Japan to evacuate, South Korea on Thursday started checking radiation levels of people coming into the country from Japan
2011 Preview: Will Korean Pharmas Follow Japanese Pharmas Lead To Survive Harsh Environment At Home?
SEOUL - Pricing pressure and increased government oversight of irregular business activities could prompt Korean pharmaceutical companies to focus on new growth strategies for 2011 such as cooperative deals with multinational companies and exports into new emerging markets like China, according to Korean analysts